ID: ALA5289404

Max Phase: Preclinical

Molecular Formula: C15H10N6OS

Molecular Weight: 322.35

Associated Items:

Representations

Canonical SMILES:  N#CC(C#N)=C1SC(n2nc(O)cc2N)=CN1c1ccccc1

Standard InChI:  InChI=1S/C15H10N6OS/c16-7-10(8-17)15-20(11-4-2-1-3-5-11)9-14(23-15)21-12(18)6-13(22)19-21/h1-6,9H,18H2,(H,19,22)

Standard InChI Key:  UBRAFIABPGDNPA-UHFFFAOYSA-N

Associated Targets(Human)

SF-268 49410 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 322.35Molecular Weight (Monoisotopic): 322.0637AlogP: 2.44#Rotatable Bonds: 2
Polar Surface Area: 114.89Molecular Species: ACIDHBA: 8HBD: 2
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 5.76CX Basic pKa: 1.88CX LogP: 3.04CX LogD: 1.62
Aromatic Rings: 2Heavy Atoms: 23QED Weighted: 0.82Np Likeness Score: -1.09

References

1. Sharma PC, Bansal KK, Sharma A, Sharma D, Deep A..  (2020)  Thiazole-containing compounds as therapeutic targets for cancer therapy.,  188  [PMID:31926469] [10.1016/j.ejmech.2019.112016]

Source